Moghaddam A, Reinton N, Dalgard O
Fürst Medisinsk Laboratorium, Ulleval universitetssykehus, Oslo, Norway.
J Viral Hepat. 2006 Apr;13(4):222-9. doi: 10.1111/j.1365-2893.2005.00678.x.
The genotypes of hepatitis C virus (HCV) in serum of patients have been described as independent predictors of success of antiviral therapy. Therefore, different antiviral regimens have been proposed depending on the infecting HCV genotype. HCV strain is usually determined by polymerase chain reaction (PCR) amplification of genome followed by sequencing or by line-probe assays. We report a new one step real-time PCR assay for genotyping of HCV strains that are prevalent in patients in Norway. HCV types 1, 2 and 3a were genotyped unambiguously in 37 patient serum samples with 100% correlation to genotyping by nucleotide sequence analysis and line-probe assays. Genotyping could also be confirmed against an HCV genotype panel from the National Institute for Biological Standards and Control. This assay does not require manipulation of amplified PCR products, it involves very little hands on and analysis time. This assay can be used for rapid genotyping of HCV-RNA in infected patients to aid physicians decide suitability of patients for treatment and subsequent length of treatment.
患者血清中丙型肝炎病毒(HCV)的基因型已被描述为抗病毒治疗成功的独立预测指标。因此,根据感染的HCV基因型,已提出了不同的抗病毒治疗方案。HCV毒株通常通过基因组的聚合酶链反应(PCR)扩增,然后进行测序或线性探针分析来确定。我们报告了一种新的一步实时PCR检测方法,用于对挪威患者中流行的HCV毒株进行基因分型。在37份患者血清样本中,1型、2型和3a型HCV被明确基因分型,与通过核苷酸序列分析和线性探针分析进行的基因分型有100%的相关性。基因分型也可以对照来自国家生物标准与控制研究所的HCV基因型标准品进行确认。该检测方法不需要对扩增的PCR产物进行操作,操作和分析时间极少。该检测方法可用于对感染患者的HCV-RNA进行快速基因分型,以帮助医生确定患者是否适合治疗以及后续的治疗时长。